Molecular Targeting Technologies, Inc. to Present EvaThera, Long-Acting Peptide Receptor Radionuclide Therapy Platform, at BioFuture™ 2023

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5^th, at Lotte New York Palace hotel. This year, registered, in-person attendees can view MTTI’s presentation live, and get advance access to a recorded version beginning September 1, five weeks prior to the actual event.

Jianwei Xu, PhD, Chief Business Officer will introduce MTTI’s EvaThera, the first long-acting, targeted peptide receptor radionuclide therapy (PRRT) platform.

PRRT delivers killing radiation directly to cancer cells using unique peptides to target biomarkers on those cancers. This class of therapeutics has seen explosive growth since 2018, projected to continue at 34% CAGR over the next decade.

Chris Pak, founder and CEO of MTTI noted, “EvaThera provides next-generation efficacy for many hard-to-treat cancers. We’re excited to expose the broad BioFuture audience to our high value, long-acting PRRT platform.”

Sara Demy, CEO of Demy-Colton commented, “We are delighted that Molecular Targeting Technologies, Inc. will be presenting. BioFuture gathers today’s very best innovators, investors and business leaders to discuss the future of healthcare and potential game-changing technologies, like EvaThera, that will drive that future.”

ABOUT BIOFUTURE

BioFuture, produced by Demy-Colton, is a conference convening future-focused healthcare thinkers, top investors, stakeholders and cutting-edge companies to “Reimagine the Future of Healthcare”. BioFuture 2023 will be held in-person in New York City on October 4-6 at Lotte New York Palace Hotel, with a virtual access option for digital partnering and recorded content on October 10-12. BioFuture features multiple tracks of plenary sessions, presenting companies, workshops, networking, and an opportunity to schedule one-to-one meetings. BioFuture was founded by Demy-Colton, a leading life sciences and digital health events organization, with a long history of producing high-quality events that build networks between innovative life sciences companies and industry stakeholders.

ABOUT Molecular Targeting Technologies, Inc.

MTTI is a clinical-stage company developing innovative targeted radiotherapeutics for rare cancers with high unmet needs. MTTI’s pipeline includes: EBTATE^® (ongoing clinical studies in neuroendocrine [“NET”]; Hürthle cell thyroid [HTC], and Nasopharyngeal [NPC] cancers) and EBRGD™ for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).